If you're looking the next up-and-coming stocks then look no further than Cabot Small-Cap Confidential. We limit the circulation of our advisory so that our subscribers own the stocks before the big institutions start buying them.
Each month Chief Analyst Thomas Garrity will present a new small-cap stock with his in-depth research. You'll see many stocks from emerging technologies, including mobile telecommunications, biotech, cyber security, genetic medicine, bio-pharmaceuticals, sensors, robotics and other fields with unlimited upside potential.
Cabot Small-Cap Confidential's focus is on finding undervalued and little-known small-cap companies with big ideas that serve very large markets. The advisory recommends one stock each month, and usually holds them as long-term investments. The advisory does not present a model portfolio—i.e., there's no cash position, weightings, etc.; however, all recommendations are followed up weekly with buy, hold and eventually sell ratings.The performance shown is the average gain of Cabot Small-Cap Confidential stocks since inception on 10/8/07, excluding current holdings as of 6/29/15.
235% in Baxano Surgical
187% in Ovascience
148% in Cardiovascular Systems
116% in Cerus
Navgiate the fast-paced world of small-cap stocks with Cabot Small-Cap Confidential. This limited-circulation advisory will help you find the technologies of tomorrow, with virtually limitless profit opportunities.
Sign up now for a risk-free trial subscription to Cabot Small-Cap Confidential. If you don’t like it, you'll receive a pro-rated refund.
What our Customers say about Small-Cap Confidential
Thank you very much for the advice. I really appreciate your input. Thanks for all the good work in the letter.
W. Yeung, Alhambra, California
I just want to take a moment to congratulate you on your performances. Not only have many of your recommendations increased by double digits recently, but they do so even when the markets go down. Thanks in advance and congratulations again. You are by far the best analyst I have seen!
M. Paquet, Québec, Canada
I find it imperative to again congratulate you on the best investment service I have ever subscribed to. Never have I had a service that I can count on a review of every stock in the portfolio on a weekly basis, sound advice as to when to take profits, differentiation of the stocks to buy based on price and market conditions, and complete analysis of a stock when it is recommended. I also must confess my selfish happiness that the service is for limited number of subscribers. This is not a one-lucky-stock service. While I have taken a couple of small losses, my profits following your advice has been exceptional. In my book, you are the number one service I have ever subscribed to. I appreciate being able to read your work on a weekly basis. On behalf of all of your subscribers, thank you for your very hard work and impressive insight.
Ron A., Palm Beach, Florida
Are you ready to get started with your risk-free trial subscription?